Conatus Pharmaceuticals Inc. | Business Contracts

Executive Employment Agreement, dated February 1, 2023, by and between the Company and Alfred P. Spada, Ph.D (Filed With SEC on January 3, 2023)

Form of Warrant Amendment (Filed With SEC on July 12, 2022)

Engagement Letter, dated March 1, 2022, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on March 25, 2022)

Letter Agreement by and between Histogen, Inc. and Allergan Sales, LLC, dated March 18, 2022 (Filed With SEC on March 22, 2022)

First Amendment to Lease, by and between Histogen Inc. and San Diego Sycamore, LLC, dated as of June 25, 2021 (Filed With SEC on June 25, 2021)

Amendment No. 4 to Amended and Restated License Agreement and Amendment No. 3 to Amended and Restated Supply Agreement, dated January 17, 2020, by and between Histogen Inc. and... (Filed With SEC on February 7, 2020)

Agreement and Plan of Merger, dated January 28, 2020, by and among Conatus Pharmaceuticals Inc., Chinook Merger Sub, Inc. and Histogen Inc (Filed With SEC on January 28, 2020)

Form of Registration Rights Agreement (Filed With SEC on July 12, 2022)

Form of Securities Purchase Agreement (Filed With SEC on July 12, 2022)

Form of Placement Agent Warrant (Filed With SEC on July 12, 2022)

Form of Series B Warrant to Purchase Common Stock (Filed With SEC on July 12, 2022)

Form of Series A Warrant to Purchase Common Stock (Filed With SEC on July 12, 2022)

Form of Pre-Funded Warrant (Filed With SEC on July 12, 2022)

Consulting Agreement, dated April 29, 2022, by and between the Company and Latterich Consulting Service LLC (Filed With SEC on April 29, 2022)

Form of Registration Rights Agreement between Histogen Inc. and the investors therein, dated March 22, 2022 (Filed With SEC on March 25, 2022)

Form of Securities Purchase Agreement between Histogen Inc. and the investors therein, dated March 22, 2022 (Filed With SEC on March 25, 2022)

Form of Placement Agent Warrant (Filed With SEC on March 25, 2022)

Description of Securities (Filed With SEC on March 10, 2022)

Form of Placement Agent Warrant (Filed With SEC on December 16, 2021)

Form of Warrant (Filed With SEC on December 16, 2021)

Form of Securities Purchase Agreement (Filed With SEC on December 16, 2021)

Form of Registration Rights Agreement (Filed With SEC on December 16, 2021)

Executive Agreement, dated November 5, 2021, by and between the Company and Steven J. Mento, Ph.D (Filed With SEC on November 8, 2021)

Amendment to Engagement Letter between Histogen Inc. and H.C. Wainwright & Co., LLC, dated as of June 6, 2021 (Filed With SEC on June 8, 2021)

Form of Securities Purchase Agreement (Filed With SEC on June 8, 2021)

Form of Placement Agent Warrant (Filed With SEC on June 8, 2021)

Form of Warrant (Filed With SEC on June 8, 2021)

Consulting Agreement, by and between the Company and Gail K. Naughton, Ph.D., effective as of June 1, 2021 (Filed With SEC on May 27, 2021)

Confidential Severance Agreement and General Release, by and between the Company and Gail K. Naughton, Ph.D., dated May 26, 2021 (Filed With SEC on May 27, 2021)

Form of placement agents warrant (Filed With SEC on December 29, 2020)

Form of Common Warrant (Filed With SEC on December 29, 2020)

Engagement Letter between Histogen Inc. and H.C. Wainwright & Co., LLC, dated as of December 28, 2020 (Filed With SEC on December 29, 2020)

Form of pre-funded warrant (Filed With SEC on December 29, 2020)

Form of Securities Purchase Agreement (Filed With SEC on December 29, 2020)

Engagement Letter between Histogen Inc. and H.C. Wainwright & Co., LLC, dated as of November 10, 2020 (Filed With SEC on November 12, 2020)

Form of Securities Purchase Agreement (Filed With SEC on November 12, 2020)

Form of Placement Agent Warrant (Filed With SEC on November 12, 2020)

Form of Warrant (Filed With SEC on November 12, 2020)

Collaborative Development and Commercialization Agreement, dated as of October 26, 2020, by and between the Company and Amerimmune LLC (Filed With SEC on October 27, 2020)

Specimen Common Stock Certificate (Filed With SEC on August 13, 2020)

Purchase Agreement, dated as of July 20, 2020, by and between the Company and Lincoln Park (Filed With SEC on July 20, 2020)

Registration Rights Agreement, dated as of July 20, 2020, by and between the Company and Lincoln Park (Filed With SEC on July 20, 2020)

Employment Agreement between Histogen, Inc. and Susan A. Knudson dated May 27, 2020 (Filed With SEC on May 28, 2020)

Form of Stock Option Grant Notice and Option Agreement (2020 Incentive Award Plan) (Filed With SEC on May 28, 2020)

2020 Incentive Award Plan, effective May 26, 2020 (Filed With SEC on May 27, 2020)

First Amendment to Sublease Agreement, dated March 30, 2020, by and between Conatus Pharmaceuticals Inc. and Pacific Real Estate Partnership (Filed With SEC on March 30, 2020)

Description of Capital Stock (Filed With SEC on March 11, 2020)

Sublease Agreement, dated December 18, 2019, by and between the Registrant and Pacific Real Estate Partnership (Filed With SEC on March 11, 2020)

Histogen Inc. 2007 Stock Plan (Filed With SEC on February 7, 2020)

Notice of Grant of Stock Option, dated January 24, 2019, by and between Histogen Inc. and Richard W. Pascoe (Filed With SEC on February 7, 2020)

Histogen Inc. Form of Stock Option Agreement (2007 Stock Plan) (Filed With SEC on February 7, 2020)

Amendment to Employment Agreement, dated January 27, 2020, by and between Keith W. Marshall, Ph.D. M.B.A. and Conatus Pharmaceuticals Inc (Filed With SEC on February 7, 2020)

Histogen Inc. Form of Stock Option Agreement (2017 Stock Plan) (Filed With SEC on February 7, 2020)

Histogen Inc. 2017 Stock Plan (Filed With SEC on February 7, 2020)

Executive Employment Agreement, dated April 16, 2019, by and between Histogen Inc. and Martin Latterich (Filed With SEC on February 7, 2020)

Amendment to Employment Agreement, dated January 27, 2020, by and between Alfred P. Spada, Ph.D. and Conatus Pharmaceuticals Inc (Filed With SEC on February 7, 2020)

Amendment to Employment Agreement, dated January 27, 2020, by and between Steven J. Mento, Ph.D. and Conatus Pharmaceuticals Inc (Filed With SEC on February 7, 2020)

Histogen Inc. Form of Warrant (Filed With SEC on February 7, 2020)

Amendment to Option and Employment Agreement, dated January 28, 2020, by and between Histogen Inc. and Richard W. Pascoe (Filed With SEC on February 7, 2020)

Executive Employment Agreement, dated December 11, 2018, by and between Histogen Inc. and Richard W. Pascoe (Filed With SEC on February 7, 2020)

Form of Indemnification Agreement, between Histogen Inc. and its officers and directors (Filed With SEC on February 7, 2020)

Settlement, Release and Termination Agreement, dated April 5, 2019, by and among Histogen Inc., PUR Biologics, LLC, Wylde, LLC, Christopher Wiggins and Ryan Fernan (Filed With SEC on February 7, 2020)

Termination of Stockholder Agreements, dated January 28, 2020, by and among Histogen Inc., Lordship Ventures Histogen Holdings LLC, Pineworld Capital Limited, Gail K. Naughton,... (Filed With SEC on February 7, 2020)

Second Amended and Restated Strategic Relationship Success Fee Agreement, dated January 28, 2020, by and between Histogen Inc. and Lordship Ventures LLC (Filed With SEC on February 7, 2020)

Amended and Restated Release, dated January 28, 2020, by and among Histogen Inc., Jonathan Jackson, Lordship Ventures LLC, and Lordship Ventures Histogen Holdings LLC (Filed With SEC on February 7, 2020)

Letter Agreement, dated November 8, 2019, by and between Histogen Inc. and Canaccord Genuity LLC (Filed With SEC on February 7, 2020)

Exclusive License and Supply Agreement, dated September 30, 2016, by and between Histogen Inc. and Pineworld Capital Limited (Filed With SEC on February 7, 2020)

Amended and Restated License Agreement, dated December 16, 2013, by and between Histogen Inc. and Suneva Medical, Inc (Filed With SEC on February 7, 2020)

Amended and Restated Supply Agreement, dated December 16, 2013, by and between Histogen Inc. and Suneva Medical, Inc (Filed With SEC on February 7, 2020)

Amendment No. 1 to the Amended and Restated License Agreement and Amended and Restated Supply Agreement, dated July 12, 2017, by and among Histogen Inc., Suneva Medical, Inc. and... (Filed With SEC on February 7, 2020)

Amendment No. 2 to Amended and Restated License Agreement, dated October 25, 2017, by and between Histogen Inc. and Allergan Sales, LLC (Filed With SEC on February 7, 2020)

Amendment No. 3 to Amended and Restated License Agreement and Amendment No. 2 to Amended and Restated Supply Agreement, dated March 22, 2019, by and between Histogen Inc. and... (Filed With SEC on February 7, 2020)

Conversion, Termination and Release Agreement, dated August 10, 2016, by and among Histogen Inc., Jonathan Jackson, Lordship Ventures LLC and Lordship Ventures Histogen Holdings... (Filed With SEC on February 7, 2020)

Support Agreement, dated January 28, 2020 by and among Conatus Pharmaceuticals Inc., Histogen Inc. and certain stockholders of Conatus Pharmaceuticals Inc (Filed With SEC on January 28, 2020)

Support Agreement, dated January 28, 2020, by and among Conatus Pharmaceuticals Inc., Histogen Inc. and certain stockholders of Histogen Inc (Filed With SEC on January 28, 2020)

General Release of Claims, dated October 1, 2019, by and between David T. Hagerty, M.D. and the Registrant (Filed With SEC on November 5, 2019)

General Release of Claims, dated July 1, 2019, by and between Daniel L. Ripley and the Registrant (Filed With SEC on November 5, 2019)

General Release of Claims, dated July 1, 2019, by and between Edward F. Smith, III, Ph.D. and the Registrant (Filed With SEC on November 5, 2019)

Amendment to Employment Agreement, dated July 31, 2019, by and between Michelle L. Vandertie and the Registrant (Filed With SEC on November 5, 2019)

Amendment to Employment Agreement, dated July 31, 2019, by and between Alfred P. Spada, Ph.D. and the Registrant (Filed With SEC on November 5, 2019)

Amendment to Employment Agreement, dated July 31, 2019, by and between Keith W. Marshall, Ph.D. and the Registrant (Filed With SEC on November 5, 2019)

Amendment to Option, Collaboration and License Agreement, dated September 30, 2019, by and between Novartis Pharma AG and Conatus (Filed With SEC on October 4, 2019)

Amendment to Employment Agreement, dated July 31, 2019, by and between Steven J. Mento, Ph.D. and Conatus Pharmaceuticals Inc (Filed With SEC on August 1, 2019)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Conatus Pharmaceuticals Inc. 2013 Incentive Award Plan (Filed With SEC on August 1, 2019)

Conatus Pharmaceuticals Inc. (84)